Filing Flows › Health Care › Allogene Therapeutics (ALLO)
Allogene Therapeutics (ALLO) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 12, 2026 · Allogene Therapeutics (ALLO) Q2 2026 earnings results →
Q2 2026 920¢ of every $1 of revenue lost
Allogene Therapeutics made $4.6M in Q2 2026. Operating margin n/m, net loss $42.7M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 12, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $4.6M in Q2 2026.
Operating costs exceeded revenue by $46.9M, an operating margin of -1011.2%. The quarter ended with a net loss of $42.7M.
Operating cash flow was −$32.0M. Non-cash charges added back $2.6M of depreciation and amortization and $12.4M of share-based compensation. Working capital and other items used $4.4M. Capital expenditures of $150K exceeded it, leaving free cash flow of −$32.1M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 12, 2026 | $4.6M | — | n/m | −$42.7M | −$32.0M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Allogene Therapeutics
We are a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. We are developing a pipeline of “off-the-shelf” T cell product candidates that are designed to target and kill cancer cells in patients or eliminate pathogenic autoreactive cells in patients with autoimmune disorders. Our engineered T cells are allogeneic, meaning they are derived from healthy donors for intended use in any patient, rather than from an individual patient for that patient’s use, as in the case of autologous T cells. We believe this key difference will enable us to deliver readily available treatments faster, more reliably, at greater scale, and to more patients.
In its own words, from its 10-K, filed Mar 12, 2026.
Allogene Therapeutics against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ALLO Allogene Therapeutics | Q2 2026 | $4.6M | — | n/m |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: Allogene Therapeutics 10-Q on SEC EDGAR · CIK 1737287 · Biological Products, (No Diagnostic Substances)
13F: who owns ALLO and who is buying
More on ALLO
- How Allogene Therapeutics makes money: revenue by segment
- Allogene Therapeutics next earnings date and what analysts expect
- Allogene Therapeutics stock forecast, price target and fair value
- Who owns Allogene Therapeutics stock: holders, funds and Congress trades
- Allogene Therapeutics guidance and outlook
- Allogene Therapeutics recalls, complaints and regulation
History
Every quarter: Q2 2026 results